Abstract
7557 Background: Pazopanib is an oral angiogenesis inhibitor targeting VEGFR, PDGFR and c-kit. The present phase II open-label trial (NCT00367679; VEG105290) was designed to determine the clinical/biological activity and the safety of pazopanib given preoperatively in patients with stage I-II NSCLC. Methods: After initial biopsy and prior to scheduled surgery, eligible patients received pazopanib 800 mg QD for 2–6 weeks followed by a washout period of 7 days prior to surgery. The primary endpoint was tumor volume reduction assessed by high resolution CT (HRCT) images performed prior to and after pazopanib treatment. Secondary endpoints were response according to RECIST criteria and safety. The sequence of centrally reviewed scans was blinded. Analysis of surgical specimens as well as pre-and post-treatment plasma samples allowed comparative biological analyses to be performed. The target accrual was 33 patients between February 2007 and February 2008. Results: 26 patients were enrolled by November 30 2007, by which time 23 had pre and post treatment HRCT available. Median age was 65 yrs (51–79), 62% were female. Histologies were adenocarcinoma 62%, squamous cell 15%, and other NSCLC 23%. Stage IA: 16 patients; stage IB: 9 patients; stage IIA: 1 patient. Median duration of therapy was 18 days. Twenty pts (87%) had a reduction in tumor volume after pazopanib treatment. Tumor changes ranged from -86% to +17%. Three patients had a partial response. Grade 3 toxicities were seen in 3 patients: including ALT increase (2), hypertension (1), dyspnea (1), pneumonia (1), urinary tract infection (1), and lymphopenia (1). No grade 4 toxicities were seen. One patient discontinued due to Aes. Conclusions: Short-term pazopanib treatment demonstrated clear single-agent activity in early stage NSCLC with a favorable tolerability profile in this population. Further clinical development in this setting is planned. Final results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline General Electric, Pneum Rx GlaxoSmithKline, Pneum Rx GlaxoSmithKline
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
